RNAi-siRNAI-miRNA-shRNA News: Breaking RNAi-siRNAI-miRNA-shRNA News, Comments and Articles. - Page: 4

Novel intercellular transportation system may have potential for delivering RNAi and other gene-based therapeutics

(Medical Xpress)—Important new research from UMass Medical School demonstrates how exosomes shuttle proteins from neurons to muscle cells where they take part in critical signaling mechanisms, an exciting discovery that means these tiny vehicles co...

InteRNA Technologies Secures Additional Equity Financing to Progress Lead Program for Melanoma ...

Nijmegen/Utrecht, the Netherlands, March 26, 2013 / B3C newswire / – InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing of an equity financing round. New investors participating in this round include the ‘Innovation & Investment Fund Gelderland’, managed by PPM Oost and se...

PrimeraDx to Co-Develop Companion Diagnostics with Quest Diagnostics

MANSFIELD, Mass., March 26, 2013 /PRNewswire/ -- PrimeraDx, Inc., a molecular diagnostics company, today announced it has formed a non-exclusive diagnostics co-development agreement with Quest Diagnostics (NYSE: DGX), the world's leading diagnostics information services company.  The intent of the collaboration is to co-develop and commercialize molecular diagnostic products and services with...

Allele Publishes mNeonGreen as the Brightest Monomeric Fluorescent Protein for Super-resolution Imaging

This week scientists from Allele Biotechnology and its partner non-profit research institute, the Scintillon Institute, present their latest fluorescent protein, mNeonGreen, in the journal Nature Methods (Nature Publishing Group). In the paper, entitled “A bright monomeric green fluores

Arrowhead Induces 90% Reduction in Hepatitis B Antigens in Chimpanzee with Chronic Infection: Data Follow Previous Report of Reduction in Viral DNA

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, will host an analyst event today in New York City to discuss ARC-520, its RNAi-based candidate designed to treat chronic hepatitis B virus infection. The company will discuss the program and describe new preclinical data showing that a low dose of ARC-520 induced rapid and deep...

Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance

The authors performed a genome-wide RNAi screen for genes modifying mutant Huntingtin (mHTT) clearance, identifying NUB1 as a protein whose overexpression lowered mHTT protein amounts, rescued mHTT-induced neuronal death and improved motor function i...

Benitec Selects the Duke Clinical Research Unit as a Site for Hepatitis C Phase I/II Clinical Trial

SYDNEY and DURHAM, N.C., March 21, 2013 /PRNewswire/ -- RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced the selection of the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI), Durham, North Carolina, USA as a site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C. TT-034 is bei...

[RXi] gets patent portfolio from [Opko Health]

Concurrent with a $16.4mm private placement, RNAi therapies developer [RXi Pharmaceuticals Corp.] has acquired from [Opko Health Inc.] (small molecules, vaccines, and point-of-care and molecular diagnostics) a portfolio of RNAi-related assets.

RNAi - Technologies, Markets and Companies - 2013 Report

Dublin, Ireland (PRWEB) March 21, 2013 RNA interference (RNAi) or gene silencing involves the use of double stranded RNA (dsRNA). Once inside the cell, this material is processed into short 21-23 nucleotide RNAs termed siRNAs that are used in a se...

Tekmira: An Undervalued Pioneer In The Field Of RNAi Therapeutics

By Grant Zeng: Tekmira (TKMR) (TKM-TO) is a development stage biopharmaceutical company focused on the research and development of novel RNA interference (RNAi) therapeutics by utilizing its leading lipid nanoparticle (LNP) delivery technology. Based on this platform technology, Tekmira has built a diversified pipeline with both internal and partnered programs. (click to enlarge) Tekmira...

Study Finds New Genetic Test Better Predicts Mother's Risk of Having a Child With Fragile X Syndrome

AUSTIN, Texas, March 21, 2013 /PRNewswire/ -- Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman's risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk...

EGEN, Inc. Announces a Phase I Clinical Trial for Advanced Ovarian Cancer

HUNTSVILLE, Ala., March 19, 2013 /PRNewswire/ -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer.  The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GO...

Dicerna Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator

Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, today announced that the United States Patent and Trademark Office (USPTO) has issued patent claims specific to double-strande...

Alnylam begins dosing in Phase I clinical trial with ALN-TTRsc for treatment of ATTR

Alnylam Pharmaceuticals a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (A...

Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi ...

– ALN-TTRsc is Company’s First Subcutaneously Delivered RNAi Therapeutic to Enter Clinical Trials – – Data from Trial Expected Mid-2013 –

Mirna Therapeutics, Inc.: Series C $34.5M

Mirna Therapeutics (Austin, TX), a pre-clinical biologics company developing micro-RNA directed oncology therapies, closed a $34.5M Series C financing. Participants include Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage Univers...

Alnylam Initiates Phase I Clinical Study for ALN-TTRsc, a Subcutaneously Administered RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-TTRsc, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR). ATTR is caused by mutations in the TTR gene which cause abnormal amyloid...

Mostafa Ronaghi SVP & CTO of Illumina to Keynote at GTC’s NGS meeting, Jun. 20-21, San Francisco

San Francisco, CA, March 16, 2013 --(PR.com)-- Mostafa Ronaghi will give a keynote presentation on “The New Era of Medicine Enabled by Advancing NextGen Sequencing” at GTC’s 3rd Next Generation Sequencing Conference on June 20–21, 2013 in San Francisco, CA. The cost of DNA sequencing has been reduced by several orders of magnitude in the past decade. This dramatic reducti...

Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer

Sistemic, PCT collaborate to study SistemQC stem cell characterization technology

Sistemic, a UK-based miRNA profiling company, has signed a deal with NeoStem subsidiary Progenitor Cell Therapy (PCT) to start evaluation studies on Sistemic’s SistemQC stem cell characterization technology.

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in ...

Single injection at low end of the projected therapeutic dose range Well tolerated based on clinical chemistry markers and clinical observation Additional data to be discussed at analyst event on March 25  

Big Move To Occur In Sarepta Therapeutics

By Brian L. Wilson:Sarepta Therapeutics (NASDAQ: SRPT) is a company that I have been following quite closely after its monster rally on October 3rd 2012. I finally pulled the trigger and bought SRPT at an average cost of $26.80/share in early February of this year, which has provided almost 16% gains thus far.Not only am I interested in the pipeline potential in muscular dystrophy, but I'm overall...

Arrowhead RNAi Candidate ARC-520 Induces Greater than 90% Reduction in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus (HBV) supports findings from rodent models indicating that it can knock down HBV DNA and key viral antigens. Dr. Robert Lanford and his team at...

GeneTex to Release New Antibodies for the Study of DNA Repair in Zebrafish

IRVINE, Calif., March 14, 2013 /PRNewswire/ -- GeneTex, a leading manufacturer of high-quality antibodies, is pleased to announce that it will be launching new antibodies against phosphorylated Histone H2A.X and p53 designed for use with zebrafish samples. (Photo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) The zebrafish is being increasingly utilized as a model organism to...

Proteomic Strategies for Identification of microRNA Targets

In this review, the authors summarize the quantitative proteomic approaches being utilized for identification of miRNA targets, a key challenge in understanding the biological role of miRNAs. Expert Review of Proteomics